- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Leverage Leaders
U.S. Pharmaceuticals & Biotech Leverage Leaders
Results
49
49 companies
Medpace Holdings
Market Cap: US$8.5b
Provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
MEDP
US$305.66
7D
3.3%
1Y
-22.3%
MoonLake Immunotherapeutics
Market Cap: US$2.4b
A clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
MLTX
US$37.62
7D
-2.2%
1Y
-5.4%
Danaher
Market Cap: US$136.7b
Designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
DHR
US$196.11
7D
3.4%
1Y
-26.2%
Regeneron Pharmaceuticals
Market Cap: US$61.8b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
REGN
US$594.32
7D
12.6%
1Y
-39.5%
Akero Therapeutics
Market Cap: US$3.2b
Engages in the development of treatments for patients with serious metabolic diseases in the United States.
AKRO
US$38.87
7D
-2.5%
1Y
95.1%
NewAmsterdam Pharma
Market Cap: US$2.1b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
NAMS
US$18.88
7D
2.8%
1Y
-6.0%
Repligen
Market Cap: US$6.9b
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
RGEN
US$126.50
7D
2.6%
1Y
-26.4%
Bio-Rad Laboratories
Market Cap: US$6.7b
Manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America.
BIO
US$248.67
7D
4.2%
1Y
-15.4%
Metsera
Market Cap: US$2.7b
A clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.
MTSR
US$29.52
7D
23.7%
1Y
n/a
Arcellx
Market Cap: US$3.2b
Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
ACLX
US$58.78
7D
2.1%
1Y
9.6%
Nuvalent
Market Cap: US$5.1b
A clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
NUVL
US$73.32
7D
5.0%
1Y
3.4%
Legend Biotech
Market Cap: US$5.1b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$27.78
7D
-12.6%
1Y
-38.5%
CRISPR Therapeutics
Market Cap: US$3.1b
A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
CRSP
US$38.77
7D
8.8%
1Y
-31.0%